Objective: We investigated possible associations between neurotoxic inflammatory mediators (IMs) and anti-U1RNP antibodies (Abs) in cerebrospinal fluid (CSF) of neuropsychiatric systemic lupus erythematosus (NPSLE). Methods: Serum and CSF anti-U1RNP Abs were detected using an RNA-immunoprecipitation assay and CSF anti-U1RNP Ab levels were measured by ELISA. IFN-a, MCP-1 and IL-8 levels in CSF were determined by quantitative multiplex cytokine analysis. IM levels were compared among anti-U1RNP-positive and anti-U1RNP-negative NPSLE as well as other rheumatic disease controls (controls). Results: Anti-U1RNP Abs were detected in serum (58%) and in CSF (18%) of 82 NPSLE patients. CSF MCP-1 levels were higher in NPSLE than in controls. CSF IFN-a level was higher in CSF anti-U1RNP Ab-positive than in -negative patients or controls. When limited to serum anti-U1RNP Ab-positive patients, however, levels of all three IMs in CSF were higher in CSF anti-U1RNP Ab-positive than in -negative patients. Anti-U1RNP Ab levels in CSF correlated with CSF MCP-1, but not IFN-a and IL-8 levels. Conclusions: CSF anti-U1RNP Ab positivity is associated with increased level of CSF IFN-a. MCP-1 levels correlated with CSF anti-U1RNP Ab levels, whereas the increased CSF MCP-1 was not specific to CSF anti-U1RNP Ab-positive NPSLE. Lupus (2014) 23, 635-642.
Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease, and neuropsychiatric SLE (NPSLE) is a severe, life-threatening condition. Although the pathophysiology of NPSLE remains unclear, a particular subset of autoantibodies (auto-Abs) has been shown to be associated with neuronal injury. [1] [2] [3] Abs binding to a certain sequence of the N-methyl-D-aspartate receptor subunit NR2 (anti-NR2 Abs) cause excitatory synaptic transmissions in the central nervous system (CNS). 4 Arinuma et al. 5 reported that anti-NR2 Abs in the cerebrospinal fluid (CSF), but not in serum, were involved in diffuse central NPSLE. Okada et al. 6 reported that 13 of 14 patients (seven SLE, five mixed connective tissue disease (MCTD) or overlap syndrome, one undifferentiated CTD, one Sjo¨gren's syndrome) with aseptic meningitis attributed to CTD had serum anti-U1 ribonucleoprotein (RNP) Abs. Recently, using an RNA-immunoprecipitation assay (RNA-IPP), we found that anti-U1RNP Abs were detected in CSF; anti-U1RNP Abs in CSF could be a useful biomarker of NP manifestations in SLE. 7 In addition to auto-Abs, inflammatory mediators (IMs) have been found in the CSF of NPSLE patients. 8, 9 Previous reports showed that the levels of interferon (IFN)-a, 10 IFN-g-inducible protein (IP)-10, 11, 12 interleukin (IL)-8, 11 monocyte chemotactic protein (MCP)-1, 11,13 fractalkine (CX3CL1), 14 the regulated and normal T-cell expressed and secreted (RANTES/CCL5) chemokine 11 and IFN-g-induced monokines (MIG/ CXCL9) 11 in CSF are significantly higher in NPSLE than in non-NPSLE patients. IFN-a production in SLE is caused, at least partially, by auto-Abs binding to RNP particles released from dead or dying cells. 15, 16 Santer et al. 17 suggested that IFN-inducing activity in CSF correlates with serum anti-U1RNP Abs but not with other known antinuclear Abs. Therefore, anti-U1RNP Abs and/or their immune complexes (ICs) in CSF may play a pathogenic role in NPSLE; however, the association between CSF anti-U1RNP Abs and IMs remains unclear. In this study, we examined the levels of anti-U1RNP Abs and IMs in serum and CSF samples from NPSLE patients to determine whether such an association exists. 18, 19 NP manifestations were determined according to case definitions for NP syndromes in SLE 20 following NP testing, electroencephalography and brain magnetic resonance imaging (MRI). NP manifestations caused by other factors (e.g. concurrent non-SLE NP diseases such as infection, uremia and druginduced aseptic meningitis) were excluded from this study. After obtaining informed consent from all participants, CSF and serum samples were obtained on the same day and stored at À80 C until analysis. Control CSF samples were obtained from 15 patients with other systemic rheumatic diseases including rheumatoid arthritis (four), vasculitis (seven), Behc¸et disease (three) and tumor necrosis factor (TNF) receptor-associated periodic syndrome (one) (all anti-U1RNP Ab negative; five men and 10 women aged 42.7 AE 20.6 years). Although these patients had NP manifestations, routine laboratory analysis of CSF (e.g. protein level) was normal. The present study was carried out in compliance with the Helsinki Declaration and approved by the Kyoto University Ethics Committee Review Board (approval #E97).
Methods

Patients
CSF IM detection
CSF was routinely analyzed for total protein levels, cell number and immunoglobulin (Ig)G levels. IFN-a, IL-8 and MCP-1 levels were determined using the Procarta Õ Cytokine Assay Kit (Affymetrix Inc, Santa Clara, CA, USA) and quantitative multiplex cytokine analysis was performed with Bio-Plex Õ (Bio-Rad Laboratories, Hercules, CA, USA).
Detection of anti-RNA-binding proteins (RBPs) in serum and CSF by RNA immunoprecipitation (RNA-IPP)
RNA-IPP using HeLa-cell extracts was performed 7,21 to detect anti-U1RNP, Sm, Ro/SSA (SSA) and La/SSB (SSB) Abs in serum and CSF samples. Briefly, 10 ml of the sample was mixed with 2 mg of protein A Sepharose TM CL-4B (GE Healthcare) in IPP buffer (10 mM Tris-HCl, pH 8.0; 500 mM NaCl; 0.1% Nonidet P-40 (NP-40)) and incubated for two hours at 4 C. IgG-coated Sepharose TM beads were then washed in IPP buffer and resuspended in NET-2 buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.05% NP-40). For RNA analysis, this suspension was incubated with HeLa-cell extracts derived from 6 Â 10 6 cells for two hours at 4 C. The antigen-bound Sepharose TM was then collected, washed and resuspended in NET-2 buffer. To extract bound RNA, 30 ml of 3.0 M sodium acetate, 15 ml of 20% sodium dodecyl sulphate and 300 ml of phenol/chloroform/ isoamyl alcohol (50:50:1) solution, which is saturated with 0.1 M Tris-HCl pH 7.5 (about 100 ml/l) and contains 0.1% 8-hydroxyquinoline, were added to the Sepharose TM beads. RNA was recovered in the aqueous phase after ethanol precipitation and dissolved in electrophoresis sample buffer consisting of 10 M urea, 0.025% bromophenol blue and 0.02% xylene cyanol FF (Bio-Rad) in Trisborate-ethylenediaminetetraacetic (EDTA) buffer (90 mM Tris-HCl, pH 8.6; 90 mM boric acid; 1 mM EDTA). The RNA samples were denatured at 65 C for five minutes and then resolved by 7 M urea-10% polyacrylamide gel electrophoresis (PAGE) with silver staining (Bio-Rad). Anti-U1RNP, Sm, SSA and SSB Abs were detected as positive when U1RNA, U1-U6RNA, SSA-RNA (Y1-Y5RNA) and SSB-RNA (5S-ribosomal RNA, 7S-RNA and Y1-Y5RNA), respectively, were precipitated.
Measurement of anti-U1RNP Ab levels in CSF by enzyme-linked immunosorbent assay (ELISA)
CSF anti-U1RNP Ab levels were determined by ELISA using recombinant U1RNP (Mesacup Õ -2 test RNP, Medical and Biological Laboratories (MBL) Co., Nagoya, Japan) according to the manufacturer's protocol. CSF samples were diluted 1:5 using phosphate-buffered saline (PBS). Patient CSF was incubated as primary Abs at room temperature for two hours, and bound IgG was detected with alkaline phosphatase-conjugated anti-human IgG (Southern Biotechnology Associates Inc, Birmingham, AL, USA) at optical density (OD) 405 nm in a microtiter ELISA reader. All assays were performed in triplicate and OD 405 nm values of CSF samples were confirmed to be within the linear range of the positive control.
Statistical analysis
The nonparametric Mann-Whitney U test was used to compare levels between the means of two groups. Spearman's correlation coefficient by the rank test was used to evaluate the correlation between the anti-U1RNP Ab levels and IMs. p < 0.05 was considered to be significant.
Results
Anti-U1RNP Abs detected in serum and CSF of NPSLE patients
Auto-Abs against RBPs were examined using RNA-IPP ( Figure 1 ). Serum anti-U1RNP Abs were positive in 58% patients ( Figure 2 ). CSF anti-U1RNP Abs were detected in 15 patients (18% of all patients or 31% of serum anti-U1RNP Ab-positive patients); CSF anti-SSA Abs were detected in four patients (5% of all patients and 8% of serum anti-SSA Ab-positive patients). Both anti-U1RNP and SSA Abs in CSF were negative in patients without serum anti-U1RNP and SSA Abs. Serum and CSF anti-Sm Abs were positive in four patients and one patient, respectively. CSF anti-SSB Abs were not detected in our patients. Because of the low frequency of CSF anti-SSA/Sm Abs and our previous data, 7 we analyzed only the association between anti-U1RNP Abs and CSF IMs. There was no significant association of serum or CSF anti-U1RNP Ab positivity with NPSLE forms in our patients (Table 1) . Also, there was no correlation between serum and CSF anti-U1RNP Ab levels (data not shown; please see Sato et al. 7 ). Abs against ribosomal proteins such as 28S ribosome were detected in seven patients' sera, but not in CSF.
Association of serum anti-U1RNP Abs and CSF IMs
As shown in Figure 3 , there was no significant difference in CSF IFN-a and IL-8 levels between serum anti-U1RNP Ab-positive patients and controls. CSF MCP-1 level was significantly elevated in NPSLE compared with controls.
Association of CSF anti-U1RNP Abs and CSF IMs
IFN-a levels in CSF anti-U1RNP Ab-positive patients, but not in CSF anti-U1RNP Ab-negative, were significantly higher than in controls (Figure 4(a) ). CSF MCP-1 levels in NPSLE patients were markedly elevated irrespective of CSF anti-U1RNP Ab positivity. CSF anti-U1RNP Abs were not detected in serum anti-U1RNP-negative patients. When limited to serum anti-U1RNP Ab-positive patients, CSF levels of all three IMs were higher in CSF anti-U1RNP Ab-positive patients than in CSF anti-U1RNP Ab-negative patients (Figure 4(b) ).
Correlation of anti-U1RNP Ab levels with IM concentrations in CSF
Among 15 CSF anti-U1RNP Ab-positive patients, enough of 12 CSF samples remained for determination of anti-U1RNP Ab levels by ELISA. In NPSLE patients with CSF anti-U1RNP Abs, the Ab level correlated with CSF MCP-1 concentration but not with CSF IFN-a ( Figure 5 ). CSF IL-8 concentration did not correlate with CSF anti-U1RNP Ab level (data not shown).
Discussion
We previously showed that CSF anti-U1RNP Abs detected by RNA-IPP are more specific markers for primary central NPSLE than CSF IL-6 concentration and IgG index in serum anti-U1RNP Ab-positive patients. 7 However, how CSF anti-U1RNP Abs are correlated with the NPSLE pathogenesis remains unclear. To solve this question, we collected CSF samples from SLE patients with a broad range of NP manifestations, including from patients whose NP symptoms were not severe. Therefore, positivity of CSF anti-U1RNP Abs in the present study was less frequent than that in the previous study. 7 This study is the first to show a significant association between CSF anti-U1RNP Abs and particular subsets of IMs in NPSLE patients. CSF IFN-a levels were increased only in patients with CSF anti-U1RNP Abs, suggesting anti-U1RNP Ab-mediated IFN-a production in CNS. Santer et al. 17 reported that IC-containing CSF-IgG of NPSLE patients had abnormally high IFNa-inducing activity. This phenomenon was most prominent in serum anti-U1RNP Ab-positive patients, which supports our results. IFN-a was detected in CSF of NPSLE patients; therefore, it might be induced by intrathecal complexes of anti-U1RNP Ab and IC. IFN-a production has a pathogenic significance in SLE; 22 therefore, CSF anti-U1RNP Ab-associated NP manifestations should be analyzed in future studies. Although the percentages of diffuse psychiatric and neuropsychological syndromes were similar in our patients, symptoms of NPSLE patients with CSF anti-U1RNP Abs appeared to be relatively limited to headache and psychosis. In most of the patients with these diagnoses, however, CSF anti-U1RNP Abs are negative. Recently, Fragoso-Loyo et al. 23 reported that CSF IFN-a was not a useful biomarker of central NPSLE. Our data suggested that no elevation of CSF IFN-a levels occurred in patients without CSF anti-U1RNP Abs and that increased CSF IM levels may depend on the specificity of CSF auto-Abs. IL-8 and MCP-1 synthesis might be regulated by other auto-Abs in CSF. The reason why CSF IFN-a concentrations did not correlate with CSF anti-U1RNP Ab levels could not be elucidated in the present study. In our NPSLE patients, IgG index is significantly higher in CSF anti-U1RNP Ab-positive than in CSF anti-U1RNP Ab-negative patients (unpublished data); therefore, intrathecal polyclonal B-cell activation might also induce nonspecific IgG production in CNS, which inhibits FcgR IIa-mediated interferogenic activity. 17, 24 Alternatively, CSF IFN-a might be regulated by other immunologic factors than anti-U1RNP Abs in NPSLE.
Several reports have shown the clinical importance of other IMs in NPSLE patients. CSF MCP-1 has been reported as a useful biomarker that differentiates SLE-attributable NP manifestations from non-SLE-related manifestations. 9 Our results indicated that the elevated CSF MCP-1 level was not specific to CSF anti-U1RNP Ab-positive patients. When limited to NPSLE patients with serum anti-U1RNP Abs, however, CSF anti-U1RNP Ab positivity appeared to be positively correlated with the elevation of CSF MCP-1 levels. Therefore, CSF MCP-1 activation resulting from CNS injuries may stimulate the anti-U1RNP Ab production in CNS. We previously suggested the possibility of intrathecal anti-U1RNP Ab production by showing different U1-70K autoepitope patterns between serum and CSF anti-U1RNP Abs. 7 To date, only our group 7,25 and a German group 26 have published reports of CSF anti-U1RNP Ab-positive cases. A critical point of our study is the use of RNA-IPP to detect anti-U1RNP Abs in CSF. RNA-IPP is the most sensitive and specific immunological method for detecting Abs, especially against ''native'' RBPs. 27 Because less than 20 ml of a sample is enough for assay, RNA-IPP is more suitable than ELISA for detecting anti-RBP Abs in CSF, which usually cannot be obtained in a large amount from patients.
The present study does have some limitations. First, because we did not have CSF of SLE patients without NP manifestation, it is unclear whether CSF anti-U1RNP Abs exist in those patients. Second, other NPSLE-associated auto-Abs such as anti-ribosomal P were not investigated. Although we could find Abs against ribosomal antigens such as 28S-ribosomal protein in the present study, anti-ribosomal P Abs could not be specifically detected by RNA-IPP assay. Previous studies demonstrated that IL-6 levels in CSF may be associated with anti-NR2 Abs. 28 IL-8 and MCP-1 levels appear to be associated with other auto-Ab levels more than anti-U1RNP Ab levels. Auto-Abs against DNA-binding or associated antigens cannot be detected by RNA-IPP; therefore, an association study of anti-non-RBP Abs and CSF IMs using other assays is needed.
In conclusion, CSF anti-U1RNP Abs are associated with the elevated CSF IFN-a levels in NPSLE. CSF MCP-1 concentrations correlate with CSF anti-U1RNP Ab levels, whereas increased CSF MCP-1 is not specific for anti-U1RNP Ab-positive NPSLE.
